ArticleBioinformation2026
Clinical factors influencing serum CA125 levels and their implications for diagnosing ovarian tumors.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian tumors remain a major gynaecological health problem and are among the leading causes of cancer-related mortality among women in India. Therefore, it is of interest to evaluate serum CA125 levels in women with ovarian tumors and examine their association with clinical diagnosis and risk factors such as age, body mass index (BMI), smoking, parity, and socioeconomic status. Hence, a total of 100 patients with ovarian tumors (50 benign and 50 malignant) and 50 age-matched healthy controls were included, and serum CA125 levels were measured using ELISA. CA125 levels were significantly higher in malignant tumors (1045.28 ± 281.96 U/ml) compared with benign tumors (186.48 ± 103.20 U/ml) and controls (18.50 ± 12.35 U/ml; p < 0.005), with significant associations observed with increasing age, higher BMI, smoking status, lower parity, and higher socioeconomic status. Thus, the combined diagnostic and risk-stratification value of CA125 with demographic and lifestyles factors help improve early detection and clinical assessment of ovarian tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.